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Objective: The objective was to assess the safety and efficacy of a single intra-articular 
administration of JTA-004, a novel viscosupplement, in patients suffering from symptomatic knee 
osteoarthritis (OA) at 6 months. 
 
Design and methods: In this prospective, multicenter, double-blind phase II/III trial 
(NCT02740231), 164 patients with primary OA knee pain were randomly assigned to one of the 
three JTA-004 strengths or the comparator treatment (Hylan G-F 20) in a 1:1:1:1 ratio. Safety was 
assessed by monitoring and reporting vital signs, physical examination, adverse events and 
concomitant medications. The primary efficacy endpoint was the change from baseline at 6 months 
in WOMAC® VA3.1 pain subscale.  
 
Results: JTA-004 was shown to be well tolerated at all strengths evaluated. At 6 months, patients 
in the three JTA-004 groups showed a better improvement in pain compared to patients in the 
comparator group although statistical significance was not achieved. As the three JTA-004 
strengths had a similar efficacy, a post hoc analysis was subsequently performed between the 
pooled JTA-004 treated patients and the comparator group. The exploratory analysis showed a 
26.1±2.4 (adjusted mean±SE) mm improvement in pain in the pooled JTA-004 group vs. 15.6±4.1 
mm in the comparator group at 6 months, demonstrating a statistically significant superiority of 
JTA-004 over the comparator (p = 0.030). 
 
Conclusions: This study provides first evidences of safety and efficacy of JTA-004 in the 
treatment of symptomatic knee OA. Efficacy will be further confirmed in a subsequent pivotal 
Phase III study.  
 
